iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/2915408
HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987 - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 Feb 17;261(7):1008-12.
doi: 10.1001/jama.261.7.1008.

HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987

D C Des Jarlais  1 , S R Friedman, D M Novick, J L Sotheran, P Thomas, S R Yancovitz, D Mildvan, J Weber, M J Kreek, R Maslansky
Affiliations

HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987

D C Des Jarlais et al. JAMA. .

Abstract

Intravenous drug users are the second largest group to develop the acquired immunodeficiency syndrome, and they are the primary source for heterosexual and perinatal transmission in the United States and Europe. Understanding long-term trends in the spread of human immunodeficiency virus among intravenous drug users is critical to controlling the acquired immunodeficiency syndrome epidemic. Acquired immunodeficiency syndrome surveillance data and seroprevalence studies of drug treatment program entrants are used to trace seroprevalence trends among intravenous drug users in the borough of Manhattan. The virus entered this drug-using group during the mid-1970s and spread rapidly in 1979 through 1983. From 1984 through 1987, the seroprevalence rate stabilized between 55% and 60%--well below hepatitis B seroprevalence rates. This relatively constant rate is attributed to new infections, new seronegative persons beginning drug injection, seropositive persons leaving drug injection, and increasing conscious risk reduction.

PubMed Disclaimer

Comment in

  • Modeling the spread of HIV.
    Salzberg AM, Dolins SL, Salzberg CA. Salzberg AM, et al. JAMA. 1989 Sep 8;262(10):1329-31. doi: 10.1001/jama.1989.03430100063025. JAMA. 1989. PMID: 2761032 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types